APA (7th ed.) Citation

Y, A., JC, G., N, A., V, P., Y, G., CR, A., . . . A, A. (2025). Rituximab for the treatment of immune checkpoint inhibitor-induced glomerulonephritis. Clinical kidney journal, 19(1), sfaf373. https://doi.org/10.1093/ckj/sfaf373

Chicago Style (17th ed.) Citation

Y, Alasadi, et al. "Rituximab for the Treatment of Immune Checkpoint Inhibitor-induced Glomerulonephritis." Clinical Kidney Journal 19, no. 1 (2025): sfaf373. https://doi.org/10.1093/ckj/sfaf373.

MLA (9th ed.) Citation

Y, Alasadi, et al. "Rituximab for the Treatment of Immune Checkpoint Inhibitor-induced Glomerulonephritis." Clinical Kidney Journal, vol. 19, no. 1, 2025, p. sfaf373, https://doi.org/10.1093/ckj/sfaf373.